From the publisher feed
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned. GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lill
Read the original at The Guardian ↗Opens the original publisher page. Access, copyright and subscriptions are controlled by the publisher.
A useful next step
- Read the short publisher description here.
- Open the full report directly at the publisher.
- Compare this topic with other sources when useful.